Digital Molecular Barcoding Technology for Cancer Biomarker Discovery and Personalized Medicine-Michelle M. Chen, Ph.D-01/19/2016 - 8:30am

Event Information
Event Topic: 
Digital Molecular Barcoding Technology for Cancer Biomarker Discovery and Personalized Medicine
Event Date: 
01/19/2016 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Michelle M. Chen, Ph.D
Event Speaker Title: 
Executive Director of Business Development & Strategic Alliances
Event Speaker Company: 
Event Speaker Bio: 

Michelle Chen is a biotech executive and entrepreneur with broad experience in drug development, diagnostics and life science industries and focus on company building, business development, partnerships, marketing and R&D. Prior to NanoString, she was an advisor to a number of biotech startup CEOs, founders and investors. Before that, Michelle worked in leadership roles at multi-national companies such as Roche/Genentech, Applied Biosystems, Agilent Technologies and small biotechs such as Scios and Abgenix. While at the Roche group, she initiated and drove a number of successful companion diagnostic deals with big pharma companies. In addition, she led multiple oncology therapeutic licensing deals at various sizes from a few $M to >1$B and served on the Avastin franchise team as well as Lung Cancer Disease Strategy Team (Rx and Dx). While in global marketing and public health at Applied Biosystems, she helped grow a $160M qPCR consumable business at a double-digit rate and launched H1N1 pandemic flu diagnostic solutions (platform and assays) in 2009. When she was in R&D, she led an assay development group and worked on a number of drug candidates, one of which was later approved for colorectal cancer treatment known as Vectibix®.

Event Details
Event Details: 

NanoString Technologies provides life science tools for translational research and diagnostics applications. The company’s core platform, the nCounter® Analysis System is based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology under Dr. Leroy Hood. It enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. In 2013 NanoString launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. This talk focuses on the technology and the use of technology for personalized medicine.